1. Home
  2. AIDX vs LPCN Comparison

AIDX vs LPCN Comparison

Compare AIDX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$1.92

Market Cap

58.8M

Sector

Health Care

ML Signal

N/A

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$7.39

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIDX
LPCN
Founded
N/A
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
61.8M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
AIDX
LPCN
Price
$1.92
$7.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
280.5K
124.1K
Earning Date
N/A
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$74.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.87
$2.52
52 Week High
$14.09
$12.37

Technical Indicators

Market Signals
Indicator
AIDX
LPCN
Relative Strength Index (RSI) 4.91 41.10
Support Level N/A $2.87
Resistance Level $3.08 $8.35
Average True Range (ATR) 0.44 0.72
MACD 0.02 -0.15
Stochastic Oscillator 7.05 9.93

Price Performance

Historical Comparison
AIDX
LPCN

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: